Recombinant human erythropoietin and high flux haemodiafiltration

Nephrol Dial Transplant. 1995:10 Suppl 6:51-4. doi: 10.1093/ndt/10.supp6.51.

Abstract

Since 1982, 32 uraemic patients were treated in our institution by high flux haemodiafiltration (H-HDF) in order to shorten significantly the dialytic treatment session. H-HDF used a high surface area filter (1.4-1.9 m2) with high hydraulic permeability (polyacrylonitrile and polysulfone), at high blood flow (450 ml/min) and high rates of reinfusion of substitution fluid (22 l/session). In this way the dialytic session was shortened to 140 +/- 19 min, maintaining a good cardiovascular stability and high dialytic efficiency (Kt/V > 1.1). Human recombinant erythropoietin rHuEpo introduced in the therapy of this group in 1987 has resulted in an improvement of renal anaemia, but also a prolongation of the time of dialytic treatment due to a decrease in the efficiency of filters. During the period of the study, the treatment time increased from 140 +/- 19 min to 168 +/- 25 min with a concomitant increase of haematocrit and haemoglobin (from 24% to 36% and from 7.9 to 10.5 g/dl, respectively). H-HDF maintains a noticeable increase in dialytic efficacy with good cardiovascular stability, but the goal of a significant reduction in the time of treatment can no longer be obtained.

MeSH terms

  • Adult
  • Aged
  • Anemia / blood
  • Anemia / drug therapy
  • Anemia / etiology
  • Erythropoietin / adverse effects*
  • Erythropoietin / therapeutic use
  • Female
  • Hematocrit
  • Hemodiafiltration*
  • Humans
  • Male
  • Middle Aged
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Time Factors
  • Uremia / complications
  • Uremia / drug therapy
  • Uremia / therapy

Substances

  • Recombinant Proteins
  • Erythropoietin